| abstract |
The present invention is directed to general formula (I) wherein R 1 and R 2 are independently of each other —H or —F, R 3 is —CH 3 or —CF 3 , and Ar is (a) Or (b)), or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor-mediated effects in different target tissues, particularly in uterine versus breast tissue. Thus, the progestins of the present invention can be used for contraception (especially in estrogen-free oral contraceptives), hormone replacement therapy and treatment of gynecological disorders, optionally in combination with estrogens. The present invention further relates to methods for selectively modulating progesterone receptor-mediated effects in different target tissues or organs. |